DLBCL Treatment Breakthrough
Epcoritamab-Lenalidomide Combination Reduces DLBCL Progression Risk 60% in Phase 3 Trial
Anonymous
Key Points
1
In EPCORE DLBCL-4, PFS improvements were demonstrated under two censoring analyses: HR 0.40 (95% CI 0.30–0.55) with p < 0.0001, and HR 0.44 (95% CI 0.33–0.60) with p < 0.0001, reflecting US and non-US data considerations.
2
The trial comparator was the standard-of-care regimen rituximab plus gemcitabine plus oxaliplatin (R-GemOx), used as the control arm for measuring PFS benefit.
3
Epcoritamab is a subcutaneously administered T-cell engaging bispecific antibody, forming the backbone of the combination with lenalidomide in EPCORE DLBCL-4.
4
The safety profile of the epcoritamab–lenalidomide combination was consistent with the known tolerability of the individual agents, with no new safety signals highlighted in the topline data.
5
Genmab disclosed the topline EPCORE DLBCL-4 results via a Form 6-K foreign issuer filing, underscoring the official regulatory communication accompanying the data release.
A landmark cancer drug combination just cut the risk of disease worsening or death by roughly 60% in a tough-to-treat blood cancer. AbbVie and Genmab announced that their Phase 3 EPCORE DLBCL-4 trial met its primary goal, showing epcoritamab plus lenalidomide dramatically outperformed the standard chemotherapy regimen R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma, according to MarketWatch.
The trial produced a hazard ratio of 0.40 — meaning patients on the new combination were 60% less likely to see their disease progress or die compared to those on standard care. The p-value came in well below 0.0001, making the result about as statistically clear-cut as clinical trials get, according to Benzinga.
What the Numbers Actually Mean for Patients
The trial used two different statistical analyses to satisfy regulators in different countries. The first showed a hazard ratio of 0.40 (95% CI: 0.30–0.55). The second, designed for non-US regulatory standards, came in at 0.44 (95% CI: 0.33–0.60). Both carried p-values below 0.0001, according to GuruFocus. Either way, the result is the same: the combination crushed the chemotherapy control arm.
Epcoritamab is a bispecific antibody — a drug that grabs a T cell and a cancer cell at the same time, forcing the immune system to destroy the tumor. Adding lenalidomide, an immune-boosting pill, appears to supercharge that attack. AbbVie's chief medical officer Dr. Roopal Thakkar called the result a potential "chemotherapy-free, fixed-duration regimen" that could replace "traditional intensive therapies" for patients with few good options.
Why R-GemOx Was the Bar to Beat
For years, patients with R/R DLBCL who could not tolerate stem cell transplants had one main option: R-GemOx, a cocktail of rituximab, gemcitabine, and oxaliplatin. It works for some patients, but it brings harsh side effects — nerve damage, nausea, and low blood counts — and its long-term results are modest at best.
DLBCL is the most common aggressive blood cancer. About 30–40% of patients relapse after their first treatment. That group has historically had very poor outcomes. Beating R-GemOx by this wide a margin puts epcoritamab plus lenalidomide in a strong position to become the new standard of care for transplant-ineligible patients in the second-line setting, according to MarketWatch.
Safety Profile Holds, No New Red Flags
Bispecific antibodies like epcoritamab are known to cause cytokine release syndrome — a flu-like immune overreaction that can become serious. The companies reported that the safety profile in EPCORE DLBCL-4 was consistent with what was already known about both drugs individually. No new safety signals emerged from the topline data, according to Benzinga.
The drug is also given as a quick under-the-skin injection rather than a multi-hour IV drip, as required by R-GemOx. Genmab CEO Jan van de Winkel said the company is eager to "engage with global regulators to bring this subcutaneous combination to patients as quickly as possible." Genmab disclosed the results through a Form 6-K filing, the official foreign issuer regulatory channel.
What Comes Next: Regulators, Rivals, and Remaining Questions
AbbVie and Genmab say they will submit the data to global regulators, including the FDA and EMA, aiming for a label expansion that could allow epcoritamab to move from a third-line niche treatment into routine second-line use. Analysts at Jefferies called the HR of 0.40 "near the best-case scenario" and see a major commercial opportunity ahead, according to GuruFocus.
The big unanswered question is overall survival — whether patients live longer, not just longer without progression. That data may take another 12–18 months to mature. The companies will present the full topline results at a future medical meeting. In the meantime, the 60% risk reduction gives epcoritamab a strong head start over rivals in the crowded R/R DLBCL space.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
40
Reach
52
A
AnonymousAuthor
